Trial Profile
Harmonizing Optimal Strategy for Treatment of Coronary Artery Diseases Trial - Comparison of REDUCTION of PrasugrEl Dose & POLYmer TECHnology in ACS Patients (HOST REDUCE POLYTECH RCT Trial) Comparison of the Efficacy and Safety of Biostable Polymer DES (Promus PremierTM, Xience Alpine®, and Resolute Onyx®) With Biodegradable Polymer DES (Biomatrix®, Biomatrix Flex®, Nobori®, Ultimaster®,Synergy®, and Orsiro®)and Conventional Dose Prasugrel Therapy With Reduced Dose Prasugrel Therapy in Acute Coronary Syndrome Patients Treated With Percutaneous Coronary Intervention
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 06 Jun 2022
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Prasugrel
- Indications Acute coronary syndromes
- Focus Adverse reactions
- Acronyms HOST-III-REDUCE-POLYTECH-RCT
- 04 Apr 2022 Results of subgroup analysis assessing efficacy and safety of de-escalation of prasugrel therapy in patients with Diabetes Melitus presented at the 71st Annual Scientific Session of the American College of Cardiology
- 18 Nov 2020 Results published in the Circulation
- 02 Sep 2020 Primary endpoint (Antiplatelet arm : major adverse cardiovascular event (MACE), defined as a composite of all death, MI, stent thrombosis, repeat revascularization, CVA, and BARC class 2 bleeding) has been met according to the results published in the Lancet